Abstract
Experimental and clinical findings have shown in the past decade that specific proinflammatory mediators and their cognate receptors are upregulated in epileptic brain tissue. In particular, the IL-1 receptor (R)/Toll-like receptor (TLR) signaling pathways are activated in experimental models of seizures and in human epileptic tissue from drug-resistant patients. Pharmacological targeting of these proinflammatory pathways using selective receptor antagonists, or the use of transgenic mice with perturbed cell signaling, demostrated that the activation of IL-1R type 1 and TLR4 by their respective endogenous ligands, i.e., interleukin (IL)-1b and High Mobility Group Box 1, is implicated in the precipitation and recurrence of experimentally induced seizures in rodents. This evidence highlights a new target system for pharmacological intervention to inhibit seizures by interfering with mechanisms involved in their genesis and recurrence. © Wiley Periodicals, Inc. © 2011 International League Against Epilepsy.
Author supplied keywords
Cite
CITATION STYLE
Vezzani, A., Bartfai, T., Bianchi, M., Rossetti, C., & French, J. (2011). Therapeutic potential of new antiinflammatory drugs. In Epilepsia (Vol. 52, pp. 67–69). https://doi.org/10.1111/j.1528-1167.2011.03242.x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.